diclofenac has been researched along with Cancer of Skin in 51 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 5.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| " The topical NSAID diclofenac works as a nonspecific COX inhibitor and is an effective and well tolerated treatment for actinic keratosis, which is a principal precursor of cutaneous squamous cell carcinoma." | 4.84 | The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention. ( Zhan, H; Zheng, H, 2007) |
| "Prevention of nonmelanoma skin cancers remains a health priority due to high costs associated with this disease." | 2.82 | Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm. ( Alberts, DS; Bartels, HG; Bartels, P; Bermudez, Y; Curiel-Lewandrowski, C; Einspahr, JG; Hu, C; Jeter, JM; Myrdal, PB; Stratton, SP; Warneke, JA; Yozwiak, M, 2016) |
| "sBCC treated with diclofenac showed a significant decrease in Ki-67 (P < ." | 2.82 | The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial. ( Brinkhuizen, T; Frencken, KJ; Hoff, ML; Kelleners-Smeets, NW; Mosterd, K; Nelemans, PJ; Rennspiess, D; van der Horst, MP; van Steensel, MA; Winnepenninckx, VJ; Zur Hausen, A, 2016) |
| "AKs must be considered an early squamous cell carcinoma (SCC) for their probable progression into invasive SCC." | 2.66 | Current therapies for actinic keratosis. ( Conforti, C; Corneli, P; di Meo, N; Dianzani, C; Farinazzo, E; Giuffrida, R; Magaton Rizzi, G; Moret, A; Zalaudek, I, 2020) |
| "Chemoprevention of nonmelanoma skin cancer should be considered in patients likely to develop numerous, invasive, or metastatic nonmelanoma skin cancers." | 2.61 | Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. ( Council, ML; Nemer, KM, 2019) |
| "Epithelial non-melanoma skin cancer (NMSC) like actinic keratosis (AK), Bowen's disease (BD) and basal cell carcinoma (BCC) represent the most common malignancies in the fair skinned population." | 2.46 | Taking treatment decisions in non-melanoma skin cancer--the place for topical photodynamic therapy (PDT). ( Sidoroff, A; Thaler, P, 2010) |
| "Fluorouracil has been the traditional topical treatment for actinic keratoses, although imiquimod 5% cream and diclofenac 3% gel are effective alternative therapies." | 2.44 | Treatment options for actinic keratoses. ( Bedwell, SA; Downs, MR; McIntyre, WJ, 2007) |
| "Basal cell carcinoma is a semi-malignant epithelial skin tumour with a locally destructive growth pattern but a very low tendency to metastases." | 2.43 | [Non-surgical therapy of basal cell carcinoma of the head-neck region]. ( Dissemond, J; Grabbe, S, 2006) |
| "Actinic keratosis is currently believed to be an early stage in the evolution of squamous cell carcinoma." | 2.42 | Topical and light-based treatments for actinic keratoses. ( Alam, M; Goldberg, LH; Silapunt, S, 2003) |
| "The ability to manage non-melanoma skin cancers and pre-malignant lesions with topical pharmacologic agents is highly compelling." | 2.42 | Topical treatment strategies for non-melanoma skin cancer and precursor lesions. ( Fein, H; McGillis, ST, 2004) |
| "The wool hydrolysates decreased squamous cell carcinoma cells viability by up to 67% comparing to untreated cells." | 1.46 | The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment. ( Borkowska, JK; Czuwara, J; Damps, T; Konop, M; Kowalkowski, T; Laskowska, AK; Misicka, A; Prokopowicz, M; Puszko, AK; Różycki, K; Rudnicka, L; Sosnowski, P, 2017) |
| "Non-melanoma skin cancer (NMSC) is the most common form of skin cancer." | 1.40 | Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2014) |
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 1.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "Cutaneous leiomyomas are firm, round to oval, skin-coloured to brownish papules and nodules that may present as a solitary, few discrete or multiple clustered lesions." | 1.39 | Zosteriform cutaneous leiomyoma: a rare cutaneous neoplasm. ( , 2013) |
| "Non-melanoma skin cancer (NMSC) is the most common type of skin cancer in Caucasian populations." | 1.39 | Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis. ( Afaq, F; Arumugam, A; Athar, M; Chaudhary, SC; Elmets, CA; Kopelovich, L; Talwelkar, SS; Weng, Z, 2013) |
| "Nonmelanoma skin cancer is a common cancer type with increasing incidence." | 1.39 | Topical treatment with diclofenac, calcipotriol (vitamin-D3 analog) and difluoromethylornithine (DFMO) does not prevent nonmelanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "Cotreatment with sorafenib and diclofenac interrupts a positive feedback signaling loop involving extracellular signal-regulated kinase, cellular phospholipase A2, and COX." | 1.38 | Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. ( Axelrod, M; Capaldo, BJ; Gioeli, D; Jensen, K; Mackey, A; Roller, DG; Weber, MJ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 17 (33.33) | 29.6817 |
| 2010's | 30 (58.82) | 24.3611 |
| 2020's | 3 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Collins, A | 1 |
| Savas, J | 1 |
| Doerfler, L | 1 |
| Dianzani, C | 1 |
| Conforti, C | 1 |
| Giuffrida, R | 1 |
| Corneli, P | 1 |
| di Meo, N | 1 |
| Farinazzo, E | 1 |
| Moret, A | 1 |
| Magaton Rizzi, G | 1 |
| Zalaudek, I | 1 |
| Sinclair, R | 1 |
| Baker, C | 1 |
| Spelman, L | 1 |
| Supranowicz, M | 1 |
| MacMahon, B | 1 |
| El-Khalawany, M | 1 |
| Saudi, WM | 1 |
| Ahmed, E | 1 |
| Mosbeh, A | 1 |
| Sameh, A | 1 |
| Rageh, MA | 1 |
| Damps, T | 1 |
| Laskowska, AK | 1 |
| Kowalkowski, T | 1 |
| Prokopowicz, M | 1 |
| Puszko, AK | 1 |
| Sosnowski, P | 1 |
| Czuwara, J | 1 |
| Konop, M | 1 |
| Różycki, K | 1 |
| Borkowska, JK | 1 |
| Misicka, A | 1 |
| Rudnicka, L | 1 |
| Wollina, U | 1 |
| Gaber, B | 1 |
| Koch, A | 1 |
| Brummer, C | 1 |
| Faerber, S | 1 |
| Bruss, C | 1 |
| Blank, C | 1 |
| Lacroix, R | 1 |
| Haferkamp, S | 1 |
| Herr, W | 1 |
| Kreutz, M | 1 |
| Renner, K | 1 |
| Tampucci, S | 1 |
| Carpi, S | 1 |
| Digiacomo, M | 1 |
| Polini, B | 1 |
| Fogli, S | 1 |
| Burgalassi, S | 1 |
| Macchia, M | 1 |
| Nieri, P | 1 |
| Manera, C | 1 |
| Monti, D | 1 |
| Nemer, KM | 1 |
| Council, ML | 1 |
| Pommergaard, HC | 3 |
| Burcharth, J | 3 |
| Rosenberg, J | 3 |
| Raskov, H | 3 |
| Peserico, A | 2 |
| Neri, L | 2 |
| Calzavara Pinton, P | 2 |
| Catricalà, C | 2 |
| Pellacani, G | 2 |
| Peris, K | 2 |
| Pimpinelli, N | 2 |
| Arumugam, A | 1 |
| Weng, Z | 1 |
| Talwelkar, SS | 1 |
| Chaudhary, SC | 1 |
| Kopelovich, L | 1 |
| Elmets, CA | 1 |
| Afaq, F | 1 |
| Athar, M | 1 |
| Malvehy, J | 1 |
| Roldán-Marín, R | 1 |
| Iglesias-García, P | 1 |
| Díaz, A | 1 |
| Puig, S | 1 |
| Jeter, JM | 1 |
| Curiel-Lewandrowski, C | 1 |
| Stratton, SP | 1 |
| Myrdal, PB | 1 |
| Warneke, JA | 1 |
| Einspahr, JG | 1 |
| Bartels, HG | 1 |
| Yozwiak, M | 1 |
| Bermudez, Y | 1 |
| Hu, C | 1 |
| Bartels, P | 1 |
| Alberts, DS | 1 |
| Brinkhuizen, T | 1 |
| Frencken, KJ | 1 |
| Nelemans, PJ | 1 |
| Hoff, ML | 1 |
| Kelleners-Smeets, NW | 1 |
| Zur Hausen, A | 1 |
| van der Horst, MP | 1 |
| Rennspiess, D | 1 |
| Winnepenninckx, VJ | 1 |
| van Steensel, MA | 1 |
| Mosterd, K | 1 |
| Gracia-Cazaña, T | 1 |
| González, S | 1 |
| Gilaberte, Y | 1 |
| Ulrich, C | 2 |
| Dirschka, T | 1 |
| Bierhoff, E | 1 |
| Pflugfelder, A | 1 |
| Garbe, C | 1 |
| Sidoroff, A | 1 |
| Thaler, P | 1 |
| Fecker, LF | 2 |
| Stockfleth, E | 3 |
| Braun, FK | 1 |
| Rodust, PM | 2 |
| Schwarz, C | 1 |
| Köhler, A | 1 |
| Leverkus, M | 1 |
| Eberle, J | 2 |
| Micali, G | 1 |
| Lacarrubba, F | 1 |
| Dinotta, F | 1 |
| Massimino, D | 1 |
| Nasca, MR | 1 |
| Shoimer, I | 1 |
| Rosen, N | 1 |
| Muhn, C | 1 |
| Fenske, NA | 1 |
| Spencer, J | 1 |
| Adam, F | 1 |
| Akarsu, S | 1 |
| Aktan, S | 1 |
| Atahan, A | 1 |
| Koç, P | 1 |
| Özkan, S | 1 |
| Desai, T | 1 |
| Chen, CL | 1 |
| Desai, A | 1 |
| Kirby, W | 1 |
| Jadotte, YT | 1 |
| Schwartz, RA | 1 |
| Roller, DG | 1 |
| Axelrod, M | 1 |
| Capaldo, BJ | 1 |
| Jensen, K | 1 |
| Mackey, A | 1 |
| Weber, MJ | 1 |
| Gioeli, D | 1 |
| Burns, EM | 1 |
| Tober, KL | 1 |
| Riggenbach, JA | 1 |
| Schick, JS | 1 |
| Lamping, KN | 1 |
| Kusewitt, DF | 1 |
| Young, GS | 1 |
| Oberyszyn, TM | 1 |
| Liebman, TN | 1 |
| Stein, JA | 1 |
| Polsky, D | 1 |
| Tutrone, WD | 1 |
| Saini, R | 1 |
| Caglar, S | 1 |
| Weinberg, JM | 2 |
| Crespo, J | 1 |
| Peterson, SR | 1 |
| Goldberg, LH | 2 |
| Fedorocko, P | 1 |
| Hoferová, Z | 1 |
| Hofer, M | 1 |
| Brezáni, P | 1 |
| Del Rosso, JQ | 1 |
| Silapunt, S | 1 |
| Alam, M | 1 |
| McGillis, ST | 1 |
| Fein, H | 1 |
| Morton, CA | 1 |
| Dissemond, J | 1 |
| Grabbe, S | 1 |
| Berman, B | 1 |
| Bienstock, L | 1 |
| Kuritzky, L | 1 |
| Mayeaux, EJ | 1 |
| Tyring, SK | 1 |
| Hackethal, M | 1 |
| Merk, HF | 1 |
| Chia, A | 1 |
| Moreno, G | 1 |
| Lim, A | 1 |
| Shumack, S | 1 |
| Zhan, H | 1 |
| Zheng, H | 1 |
| McIntyre, WJ | 1 |
| Downs, MR | 1 |
| Bedwell, SA | 1 |
| Iraji, F | 1 |
| Siadat, AH | 1 |
| Asilian, A | 1 |
| Enshaieh, S | 1 |
| Shahmoradi, Z | 1 |
| Rivers, JK | 1 |
| McLean, DI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm[NCT00601640] | Phase 2 | 184 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change scores were computed by subtracting baseline histologic score from End of Study histologic score. Slides were formalin fixed. Histologic Score has been developed by this research group over the course of Grant (reference below). A standardized form captures data on the following criteria: basal or suprabasilar pleomorphism (atypia); inflammation; hyperkeratosis; parakeratosis. The atypia and inflammation were rated as: none (0), mild to moderate(1), and severe (2). The remaining criteria were rated as present (1) or absent (0). Histologic Scores were computed by adding together the codes for the histologic criteria. Higher scores reflected higher level of epidermal /dermal damage. (NCT00601640)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Eflornithine Hydrochloride | 0.33 |
| Diclofenac Sodium | 0.26 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 0.64 |
Putrescine is measured in nmole/g skin per biopsy. Baseline and End of Study biopsies were measured and the change was produced by subtracting baseline levels from End of Study levels. There was one baseline biopsy and one End of Study biopsy per participant. (NCT00601640)
Timeframe: 3 months
| Intervention | nmol/g skin (Mean) |
|---|---|
| Eflornithine Hydrochloride | 0.03 |
| Diclofenac Sodium | 1.45 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 0.2 |
Adverse events were compared across three treatment groups by severity determined by the clinician. All adverse events were resolved by the end of follow up. (NCT00601640)
Timeframe: 3 months
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burning and Stinging None | Burning and stinging Mild | burning and stinging Moderate | Burning and Stinging Severe | Pruritis None | Pruritis Mild | Pruritis Moderate | Pruritis Severe | Rash, Redness. Erythema-None | Rash, Redness. Erythema-Mild | Rash, Redness. Erythema-Moderate | Rash, Redness. Erythema-Severe | |
| Diclofenac Sodium | 44 | 8 | 0 | 0 | 33 | 12 | 6 | 1 | 34 | 10 | 8 | 0 |
| Eflornithine Hydrochloride | 48 | 4 | 0 | 0 | 42 | 9 | 1 | 0 | 46 | 5 | 1 | 0 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 48 | 3 | 1 | 0 | 40 | 6 | 6 | 0 | 40 | 7 | 5 | 0 |
24 reviews available for diclofenac and Cancer of Skin
| Article | Year |
|---|---|
Nonsurgical Treatments for Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Anilides; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bi | 2019 |
Current therapies for actinic keratosis.
Topics: Aftercare; Carcinoma, Squamous Cell; Chemexfoliation; Cryotherapy; Curettage; Dermoscopy; Diclofenac | 2020 |
A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.
Topics: Antineoplastic Agents; Diclofenac; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod; | 2021 |
Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Administration, Oral; Antineoplastic Agents; Carcinoma, Basal Cell; Carci | 2019 |
Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical Treatments.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-St | 2016 |
Topical treatment of field cancerization.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Diclofenac; Fluorouraci | 2009 |
Taking treatment decisions in non-melanoma skin cancer--the place for topical photodynamic therapy (PDT).
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Dermatology; Diclofenac; Humans; M | 2010 |
Treating skin cancer with topical cream.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Diclofenac; | 2010 |
Actinic keratoses: past, present and future.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamou | 2010 |
Basic pharmacology of topical imiquimod, 5-fluorouracil, and diclofenac for the dermatologic surgeon.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Diclofenac; Fluorouracil; Humans; I | 2012 |
Topical therapy for actinic keratoses, II: Diclofenac, colchicine, and retinoids.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Colchicin | 2003 |
New and emerging topical approaches for actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Ster | 2003 |
Topical and light-based treatments for actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminolevulinic Acid; Aminoquinolines; Antineoplasti | 2003 |
Topical treatment strategies for non-melanoma skin cancer and precursor lesions.
Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag | 2004 |
Non-surgical treatment of skin cancer.
Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Cyclooxygenase Inhibitors; | 2005 |
[Non-surgical therapy of basal cell carcinoma of the head-neck region].
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplas | 2006 |
Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Consens | 2006 |
[Skin cancer after organ transplantation].
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Age | 2006 |
Topical diclofenac in the treatment of actinic keratoses.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Diclofen | 2007 |
Actinic keratoses.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Australia; Cryotherapy; Diclofenac; Fluoro | 2007 |
The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention.
Topics: Administration, Topical; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhi | 2007 |
Treatment options for actinic keratoses.
Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag | 2007 |
The safety of diclofenac for the management and treatment of actinic keratoses.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma in Situ; Diclofenac; G | 2008 |
Topical therapy for actinic keratoses: current and evolving therapies.
Topics: Administration, Cutaneous; Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinom | 2006 |
6 trials available for diclofenac and Cancer of Skin
| Article | Year |
|---|---|
PHOTODYNAMIC TREATMENT WITH NANOEMULSIFIED 5-AMINOLEVULINIC ACID AND NARROW BAND RED LIGHT FOR FIELD CANCERIZATION DUE TO OCCUPATIONAL EXPOSURE TO ULTRAVIOLET LIGHT IRRADIATION.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Sq | 2018 |
Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Di | 2016 |
The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Calcitriol; Carci | 2016 |
Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Anti-Inflammatory Agents, | 2010 |
Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anti-Inflammatory Agents | 2011 |
An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Irritant; Der | 1997 |
21 other studies available for diclofenac and Cancer of Skin
| Article | Year |
|---|---|
The combined effect of CO
Topics: Antineoplastic Agents; Carbon Dioxide; Carcinoma, Basal Cell; Diclofenac; Female; Humans; Imiquimod; | 2022 |
The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Diclofena | 2017 |
Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2019 |
Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line; Cell Proliferation; Cell Survival; Diclofenac; Humans; | 2019 |
Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Calcitriol; Chemoprevention; D | 2013 |
Zosteriform cutaneous leiomyoma: a rare cutaneous neoplasm.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Diclofenac; Humans; Leiomyoma; Male; Middle Aged; R | 2013 |
Key Opinion Leader (KOL) Consensus for actinic keratosis management in Italy: the AKTUAL Workshop.
Topics: Aminoquinolines; Carcinoma, Squamous Cell; Case Management; Clinical Trials as Topic; Cryosurgery; D | 2013 |
Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice.
Topics: Administration, Topical; Animals; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Diclof | 2014 |
Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.
Topics: Animals; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Prolifera | 2013 |
Monitoring treatment of field cancerisation with 3% diclofenac sodium 2.5% hyaluronic acid by reflectance confocal microscopy: a histologic correlation.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Diclofenac; Drug Therapy | 2015 |
Physicians' opinions and clinical practice patterns for actinic keratosis management in Italy.
Topics: Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Attitude of Health | 2014 |
Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Squamous Cell; CASP8 and FADD-Like Ap | 2010 |
Current management of actinic keratoses.
Topics: Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic | 2010 |
Solar cheilosis: an ominous precursor part II. Therapeutic perspectives.
Topics: Administration, Topical; Aminoquinolines; Biopsy; Carcinoma, Squamous Cell; Cheilitis; Combined Moda | 2012 |
Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w.
Topics: Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; C | 2012 |
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; | 2012 |
Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma.
Topics: Administration, Topical; Animals; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2013 |
Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Topical treatment with diclofenac, calcipotriol (vitamin-D3 analog) and difluoromethylornithine (DFMO) does not prevent nonmelanoma skin cancer in mice.
Topics: Administration, Topical; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Diclof | 2013 |
New and emerging treatments for nonmelanomas and actinic keratoses.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Basal C | 2003 |
Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Div | 2003 |